Calprotectina fecal: utilidad en el diagnóstico diferencial de enfermedad inflamatoria intestinal y síndrome intestino irritable en adultos / Fecal Calprotectin: utility in the differential diagnosis of inflammatory bowel disease and irritable bowel syndrome in adults

Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults. (AU)

Péptidos inmunogénicos del gluten en deposiciones: nuevo método para evaluar la adherencia a la dieta en pacientes celíacos / Immunogenic gluten peptides in stools: new method to evaluate in the dietary adherence in celiac patients

Celiac disease (CD) is an autoimmune pathology caused by the ingestion of gluten in genetically susceptible people, currently considered multisystemic. The treatment of CD is a lifelong strict Gluten-Free Diet (GFD), which allows a symptomatic improvement in most patients and achieve intestinal mucosa healing confirmed with histological study. The adherence to the GFD is variable, arguing as possible factors related to failure the economic, cultural, social aspects and the consumption of gluten inadvertently. The management of celiac patients contemplates instructing in the proper follow-up of GFD and evaluating their adherence. So far, the only way to assess adherence to GFD is through surveys, self-reports of eating habits and serology, being the main disadvantage the subjectivity factor. Recently the immunogenic gluten peptides have acquired relevance for the objective evaluation of the adherence to the GFD and the measurement appears as an efficient and sensitive option to determine the gluten intake, providing relevant information for the clinical management.

Ventajas de la medición de niveles plasmáticos de infliximab en pacientes con enfermedad inflamatoria intestinal / Advantages of level measurement of infliximab in patients with with inflammatory bowel disease

Inflammatory bowel disease includes Crohn´s disease, ulcerative colitis and unclassified colitis. Conventional therapies used for treating these diseases are often insufficient orcontraindicated and biological agents have proved to be effective and safe in these cases. Infliximab is a quimeric IgG1 monoclonal anti-tumor necrosis factor antibody that is capableof inducing and mantaining clinical remission in patients with inflammatory bowel disease. Despite its proven efficacy a considerable group of patients lose response requiring changesin therapy. Serum Infliximab trough levels are correlated with clinical response, endoscopic remission and mucosal healing in patients with inflammatory bowel disease. Monitoring and adjusting therapy guided by drug serum levels have proved to be more cost-effective and safer than empiric adjustments. Current international guidelines recommend the measurement of Infliximab trough levels in the global evaluation and management of these patients to improve treatment, avoid adverse events and unnecessary costs.